Hims & Hers down as judge denies motion over end to Lilly’s Zepbound shortage

Hims & Hers (NYSE:HIMS) fell ~8% in the premarket Thursday after a court denied a motion filed by two compounding trade groups over the FDA’s decision to declare that Eli Lilly’s (NYSE:LLY) weight loss drug Zepbound